



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## COVID-19 CORRESPONDENCE

## Therapeutic potential of long-acting opioids and opioid antagonists for SARS-CoV-2 infection

Marie Eagleton<sup>1,\*</sup>, Siobhan Stokes<sup>1</sup>, Fiona Fenton<sup>1</sup> and Eamon Keenan<sup>2</sup>

<sup>1</sup>HSE National Drug Treatment Centre, Dublin 2, Ireland and <sup>2</sup>Health Service Executive, National Social Inclusion Office, Dublin, Ireland

\*Corresponding author. E-mail: [meagleton@dtcb.ie](mailto:meagleton@dtcb.ie)

**Keywords:** ACE-2 receptor; COVID-19; naltrexone; opioids; opioid antagonists; opioid substitution treatment; opioid use disorder; SARS-CoV-2; TLR-4

Editor—Aware of few reports of COVID-19 in patients undergoing opioid substitution treatment, we proposed that opioid substitution treatment may have a protective effect on clinical manifestations of COVID-19<sup>1</sup> responding to a publication proposing an interaction between opioids and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pathology.<sup>2</sup> We have not observed significant clusters of COVID-19 in the cohort of opioid substitution-treated patients, including attendees at our centre.<sup>3</sup> Establishing incidence of COVID-19 in people who use drugs is confounded by the tendency of many authors to aggregate all people who use drugs together although effects of individual drugs on immune function and viral infection differ.<sup>4,5</sup> Recent UK and US studies indicate a low incidence of COVID-19 in people who use drugs including, but not confined to, patients treated with opioid substitution treatment.<sup>6–8</sup> A US retrospective study concluded that patients with recent opioid use disorder were at higher risk for COVID-19, and that methadone, buprenorphine, and naltrexone did not alter that risk.<sup>9</sup> However, detailed examination of this study does not provide strong evidence for this. The conclusion was based on a small SARS-CoV-2-positive population, that is 210 (0.04%) of 471,520 patients with lifetime opioid use disorder and 90 (0.21%) of 43,160 patients with recent opioid use disorder. The majority had multiple co-morbidities and a third of those with lifetime opioid use disorder were older than 65 yr. The opioid used was not stated, and patients with opioid use disorder who tested negative or were asymptomatic for COVID-19 were excluded as were those who were dispensed methadone in methadone clinics.

In contrast, the unexpectedly low incidence in opioid substitution-treated patients we reported previously continues to be maintained.<sup>1</sup> In July–October 2020, we conducted

a seroprevalence study on 103 patients on opioid substitution treatment, which showed that the majority of patient samples (100; 97%) tested were negative for the presence of antibodies to SARS-CoV-2.<sup>3</sup> Low incidence continued throughout the third wave of this pandemic when case numbers peaked in Ireland with the more transmissible B.1.1.7 variant of the virus dominating. Data reported to the WHO by the Irish Health Protection Surveillance Centre (HPSC) for week 48 in 2020 to week 18 in 2021 encompassing the third wave of COVID-19 in Ireland showed more than 180 000 cases of COVID-19, representing approximately 3.6% of the Irish population.<sup>10</sup> In this period, the HPSC reported just 60 cases in ‘addiction settings’ with hospitalisations and deaths (if any) in this group under the minimum threshold number for reporting.<sup>11</sup> The HPSC indicated that 13 of these 60 cases self-reported as healthcare workers (HPSC, personal communication), inferring that there were 47 cases in the ~11 200 opioid substitution treatment population in Ireland (0.42%) – considerably lower than in the general population (3.6%). This number also includes residential settings such as alcohol treatment/detoxification centres, where patients are not on opioid substitution treatment and may still include staff not identified as healthcare workers, so the cases in the opioid substitution treatment population is probably even lower than 47.

Consideration of possible mechanisms to explain a low incidence of disease in opioid substitution treatment patients raises the possibility that specific opioids interfere with the pathogenesis of SARS-CoV-2, thereby affecting clinical manifestation of COVID-19 in the host. Review of immunomodulatory properties of opioids suggests that different opioids have a varied impact on immunity.<sup>4</sup> We have considered the widespread and varied systemic effects of opioids and opioid antagonists, their ability to stabilise cell redox balance, and their antitussive properties, which could attenuate respiratory

symptoms in COVID-19 patients (dyspnoea and cough), suggesting the possibility of a protective effect of opioid substitution treatment medications on clinical manifestations of SARS-CoV-2 infection.<sup>1</sup> The restorative effect of methadone on cellular immunity in injected drug use has been observed.<sup>12</sup> The therapeutic possibility for opioids in the treatment of COVID-19 has been identified including tramadol, given its anti-inflammatory, antioxidant, analgesic, and antitussive effects.<sup>13,14</sup> Inhibition of the interaction of SARS-CoV-2 with angiotensin-converting enzyme-2 (ACE-2) by morphine and codeine has been identified as a therapeutic strategy for COVID-19.<sup>15</sup> Other *in vitro* studies included naloxone and naltrexone among drugs that could be repurposed for treatment of COVID-19.<sup>16</sup> Moreover, *in vitro*, naltrexone suppressed production of pro-inflammatory cytokines, and in docking simulation studies disrupted interaction between ACE-2 and the receptor binding domain of the SARS-CoV-2 virus spike protein, leading to a proposal to repurpose low-dose naltrexone to treat patients with COVID-19.<sup>17</sup>

Our hypothesis is that the interaction of long-acting opioids or opioid antagonists with the ACE-2 receptor, considered the main route of viral entry into the host cell, mitigates the effects of COVID-19.<sup>18</sup> We also suggest that these drugs bind to Toll-like receptor 4 (TLR4), a trans-membrane protein critical in the initiation of the innate immune response to pathogens also implicated in the pro-inflammatory response.<sup>19,20</sup> TLR4 recognises viral and bacterial molecular patterns and components of damaged cells, and its overstimulation can lead to an aberrant inflammatory response implicating it in initiation and progression of various diseases.<sup>19</sup> Pro-inflammatory effects of opioids mediated by TLR4 have been studied, providing evidence that opioid antagonists (naloxone and naltrexone) oppose these pro-inflammatory effects in a non-stereoselective manner.<sup>21</sup> Some reject the evidence of interaction between TLR4 and opioids suggesting opioids are exclusively immune suppressive.<sup>22</sup> Others propose that opioids activate TLR4 in the central nervous system but inhibit TLR4 signalling in the peripheral immune system.<sup>23</sup> A role for TLR4 in treatment of COVID-19 by selective targeting of the TLR4–SARS CoV-2 spike protein interaction using competitive TLR4 antagonists is suggested by *in silico* studies.<sup>24</sup> A link between TLR4 signalling in host cells and SARS-CoV-2-mediated inflammation has been observed via viral spike protein binding to host TLR4, and a therapeutic strategy targeting TLR4 inhibition and ACE-2 activation has been suggested.<sup>19,20,25</sup> Our suggestion is that there is interplay between opioids, ACE-2, TLR4, and SARS-CoV-2. A TLR4-opioid ligand interferes with SARS-CoV-2–TLR4–ACE-2 signalling (Table 1).

Considering the low incidence of COVID-19 in the population on opioid substitution treatment, we suggest that the interaction of specific opioids or opioid antagonists with the immune system affects the pathogenesis of COVID-19, and that the protective mechanism is via the particular interaction of these drugs with ACE-2 and TLR4. Although the hypothesis is speculative, if correct, long-acting opioids or opioid antagonists or related drugs have potential as therapies or adjunctive therapies for COVID-19. This hypothesis could be tested by (1) analysis of COVID-19 disease patterns in patients treated with opioid substitution treatment; (2) *in vitro* studies on the effects of these drugs on viral infectivity in culture and; (3) clinical trials. The safe non-addictive opioid antagonist naltrexone, in particular, or other related drugs that do not display receptor opioid

**Table 1** Summary of evidence for the therapeutic potential of long-acting opioids and opioid antagonists in the treatment of SARS-CoV-2 infection by effects on ACE-2 and TLR-4 receptors. ACE-2, angiotensin-converting enzyme-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TLR-4, Toll-like receptor 4.

1. An unexpectedly low incidence of COVID-19 has been observed in patients treated for opioid dependency with the long-acting opioid drugs methadone and buprenorphine.<sup>1,3,6–11</sup>
2. Opioids have drug-specific and varied systemic immunomodulatory effects that may influence the response to the virus.<sup>4,5,12,14</sup>
3. Opioids have antitussive properties that could attenuate respiratory symptoms in COVID-19 patients such as shortness of breath and cough<sup>1</sup>
4. Opioids and opioid antagonists interact with the ACE-2 trans-membrane protein,<sup>15,17</sup> a molecule widely considered to be main host cell receptor for SARS-CoV-2 cell entry.<sup>18</sup>
5. Opioids interact with the membrane receptor TLR4, a component of the innate immune system implicated in the pathogenesis of SARS-CoV-2.<sup>19–21,23</sup>
6. *In vitro* and *in silico* studies aimed at repurposing drugs for treatment of COVID-19 have identified that opioids have therapeutic potential.<sup>15–17,24</sup>
7. Opioid drugs including morphine, codeine, tramadol, and the opioid antagonist naltrexone have been proposed for the treatment of COVID-19.<sup>13–15,17</sup>
8. There are ongoing trials of some opioids including naltrexone and tramadol for the treatment of COVID-19 (NCT04604704; NCT04604678; NCT04365985; NCT04454307).<sup>26</sup>
9. A strategy of selective targeting of TLR4–SARS–CoV-2 spike protein interaction using competitive TLR4 antagonists as a way of treating COVID-19 has been proposed.<sup>24,25</sup>
10. A combination therapy of diminazene aceturate (an ACE-2 activator) and novel antagonist resatorvid (a TLR4 inhibitor) has been proposed as a promising therapy for effective treatment of COVID-19.<sup>25</sup>
11. Although it is recommended that untreated opioid-dependent individuals should be promptly entered into opioid substitution treatment,<sup>27</sup> related drugs that do not activate opioid receptors such as opioid antagonists (e.g. naloxone) may offer safer treatment options as typical opioid side-effects would not be a problem.

agonist activity could be candidates as therapies for COVID-19. There are ongoing or planned trials of opioids and opioid antagonists (including naltrexone and tramadol) for treatment of COVID-19.<sup>26</sup>

Regardless of the effects of opioids on immune function, opioid substitution treatment is a key strategy in the management of patients with opioid use disorder, and the WHO recommends that untreated opioid-dependent individuals be entered into treatment.<sup>27</sup> Interactions of long-acting opioids or opioid antagonists with pathogenic mechanisms of SARS-CoV-2, particularly effects on ACE-2 and TLR4 interaction with SARS-CoV-2, merit further investigation.

## Declarations of interest

The authors declare that they have no conflicts of interest. All authors are employees of the Health Service Executive of Ireland.

## References

- Eagleton M, Stokes S, Fenton F, Keenan E. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on. *Br J Anaesth* 2020; **125**: e382–3 *Br J Anaesth* 2021; **126**: e114–6
- Lambert DG. Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability? *Br J Anaesth* 2020; **125**: e382–3
- Fenton F, Stokes S, Eagleton M. A cross-section observational study on the seroprevalence of antibodies to COVID-19 in patients receiving opiate agonist treatment. *Ir J Med Sci* 2021: 1–6. <https://doi.org/10.1007/s11845-021-02660-w>
- Franchi S, Moschetti G, Amodeo G, Sacrodate P. Do all opioid drugs share the same immunomodulatory properties? A review from animal and human studies. *Front Immunol* 2019; **10**: 2914
- Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, et al. Opioids and viral infections: a double-edged sword. *Front Microbiol* 2016; **7**: 970
- Mistler CB, Sullivan MC, Copenhaver MM, et al. Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. *J Subst Abuse Treat* 2021; **129**: 108387
- Croxford S, Emanuel E, Ibitoye A, et al. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. *Public Health* 2021; **192**: 8–11
- Cales RH, Cales SC, Shreffler J, Huecker MR. The COVID-19 pandemic and opioid use disorder: expanding treatment with buprenorphine, and combining safety precautions with telehealth. *J Subst Abuse Treat* 2021. <https://doi.org/10.1016/j.jsat.2021.108543>. Advance Access published on June 26
- Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry* 2020; **26**: 30–9
- Data extracted from WHO Health Emergency Dashboard – Ireland Situation. Available from: <https://covid19.who.int/region/euro/country/ie> (accessed 13 August 2021).
- Health Protection Surveillance Centre. Epidemiology of COVID-19 Outbreaks/Clusters in Ireland. Report prepared by HPSC on 04/05/2021. Available from: [https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/covid-19outbreaksclustersinireland/COVID-19%20Weekly%20Outbreak%20Report\\_Week172021\\_WebVersion\\_v1-Final.pdf](https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/covid-19outbreaksclustersinireland/COVID-19%20Weekly%20Outbreak%20Report_Week172021_WebVersion_v1-Final.pdf) (accessed 13 August 2021).
- Wang X, Zhang T, Ho WZ. Opioids and HIV/HCV infection. *J Neuroimmune Pharmacol* 2011; **6**: 477–89
- Tahamtan A, Tavakoli-Yaraki M, Salimi V. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. *Expert Rev Respir Med* 2020; **14**: 965–7
- El-Ashawami NE, Lashin AHA, Okasha KM, et al. The plausible mechanisms of tramadol for treatment of COVID-19. *Med Hypotheses* 2021; **146**: 110468
- Roshanravan N, Ghaffari S, Hedayati M. Angiotensin converting enzyme-2 as therapeutic target in COVID-19. *Diabetes Metab Syndr* 2020; **14**: 637–9
- Li F, Michelson AP, Foraker R, Zhan M, Payne PRO. Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2. *BMC Med Inform Decis Mak* 2021; **21**: 15
- Choubey A, Dehury B, Kumar S, Medhi B, Mondal P. Naltrexone a potential therapeutic candidate for COVID-19. *J Biomol Struct Dyn* 2020: 1–8. <https://doi.org/10.1080/07391102.2020.1820379>
- Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE-2), SARS-CoV-2 and pathophysiology of coronavirus disease (COVID-19). *J Pathol* 2020; **251**: 228–48
- Aboudounya MM, Heads RJ. COVID-19 and Toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE-2 expression, facilitating entry and causing hyperinflammation. *Mediators Inflamm* 2021; **2021**: 8874339. <https://doi.org/10.1155/2021/8874339>
- Sohn KM, Lee S-G, Kim HJ, et al. COVID-19 patients up-regulate Toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. *J Korean Med Sci* 2020; **35**: e343
- Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). *Eur J Neurosci* 2008; **28**: 20–9
- Eisenstein TK. The role of opioid receptors in immune system function. *Front Immunol* 2019; **10**: 2904
- Zhang P, Yang M, Chen C, Liu L, Wei X, Zeng S. Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. *Front Immunol* 2020; **11**: 1455
- Choudhury A, Mukherjee S. In silico studies on the comparative characterisation of the interactions of SARS-CoV-2 spike protein with ACE-2 receptor homologs and human TLRs. *J Med Virol* 2020; **92**: 2105–13
- Gadanec LK, Qaradakh T, McSweeney KR, Ali BA, Zull A, Apostolopoulos V. Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment. *Future Microbiol* 2021; **16**: 205–9
- U.S. National Library of Medicine, ClinicalTrials.gov NCT04604704; NCT04604678; NCT04365985. Retrieved from: <https://clinicaltrials.gov/ct2/results?cond=COVID-19&intr=%22Naltrexone%22&draw=2&rank=7#rowId6%20NCT04454307https://clinicaltrials.gov/ct2/show/NCT04454307?cond=COVID-19&draw=2&rank=7> (accessed 13 August 2021).
- World Health Organisation. *Maintaining essential Health services: operational guidance for the COVID-19 context* 1 June 2020. Available from: [https://apps.who.int/iris/bitstream/handle/10665/332240/WHO-2019-nCoV-essential\\_health\\_services-2020.2-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/332240/WHO-2019-nCoV-essential_health_services-2020.2-eng.pdf?sequence=1&isAllowed=y) (accessed 13 August 2021 )

doi: 10.1016/j.bja.2021.08.022

Advance Access Publication Date: 6 September 2021

© 2021 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.